Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.60 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22262591 | 1.00 | MTNR1A (0.60) | MTNR1ACREBBPBRD4ARSMYD3 | |
| SCHEMBL29659944 | 1.00 | MTNR1A (0.60) | MTNR1ACREBBPBRD4ARSMYD3 | |
| SCHEMBL4139663 | 1.00 | MTNR1A (0.60) | MTNR1ACREBBPBRD4ARSMYD3 | |
| SCHEMBL29659962 | 1.00 | MTNR1A (0.60) | MTNR1ACREBBPBRD4ARSMYD3 | |
| SCHEMBL4138599 | 0.86 | MTNR1A (0.57) | MTNR1ACREBBPBRD4ARSMYD3 | |
| SCHEMBL7951734 | 0.85 | MTNR1A (0.55) | MTNR1ACREBBPBRD4SMYD3NPC1 | |
| SCHEMBL22279962 | 0.84 | MTNR1A (0.47) | MTNR1ACREBBPBRD4ARGAA | |
| SCHEMBL4045997 | 0.83 | MTNR1A (0.55) | MTNR1ACREBBPBRD4ARSMYD3 | |
| SCHEMBL4128722 | 0.82 | MTNR1A (0.53) | MTNR1ACREBBPBRD4ARHTR1A | |
| SCHEMBL1916242 | 0.82 | MTNR1A (0.53) | MTNR1ACREBBPBRD4SMYD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396503-B2 | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| CN-111094267-B | Sulfonyl-substituted bicyclic compounds as ROR gamma inhibitors | 正大天晴药业集团股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3689860-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| EP-3689860-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| CN-111094267-A | Sulfonyl-substituted bicyclic compounds as ROR gamma inhibitors | 正大天晴药业集团股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019063015-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS RORγ INHIBITOR | 正大天晴药业集团股份有限公司 | 2019-04-04 | — | — | WO | disclosed |
| US-9328079-B2 | Process for producing optically active amine | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20150210657-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | RORC, RORA, RORB | MTNR1A 342/4885CREBBP 124/4885BRD4 253/4885 |
| US-20150210657-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | HRH3, HRH1, ATIC | MTNR1A 1880/4885CREBBP 4212/4885BRD4 3939/4885 |
| US-11396503-B2 | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor | RORC, RORA, RORB | MTNR1A 342/4885CREBBP 124/4885BRD4 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.